Phenotypic detection of clinically relevant cephalosporinases and carbapenemases

In recent years there has been an increase in multi-drug resistance (MDR) amongst gram-negative pathogens. This has impacted both hospital and community acquired infections.

The MICRONAUT-S MDR MRGN Screening plate provides an extended spectrum of critically important back-up antibiotics and meropenem screening concentrations for an improved detection of OXA-48-like type D carbapenemases.
It also offers an extended spectrum of antibiotics by introduction of the novel antibiotic combinations ceftazidime-avibactam and ceftolozane-tazobactam. 

MIC plate for AST of multi-drug resistant gram-negative bacteria (MDR phenotype)

The MICRONAUT-S MDR MRGN Screening plate offers a range of features and benefits relating to the phenotypic detection of clinically relevant resistance mechanisms. 

• Resistance determination of all relevant gram-negative bacteria (Enterobacteria, Aeromonas, non-fermenters) against antibiotics and antibiotics combinations in a standard microdilution procedure
• ​AST against the novel antibiotic combinations ceftazidime-avibactam and ceftolozane-tazobactam
• Phenotypical detection of MBL (metallo-ß-lactamases) by resistance determination against meropenem as a mono substance and in combination with the divalent cationic chelator EDTA
• Phenotypical detection of KPC (Klebsiella pneumoniae carbapenemase) by resistance determination against meropenem as a mono substance and in combination with 3-Amino-Phenyl-Borate (3-APB)
• Phenotypical detection of AMP-C (Aminopenicillin inactivating cephalosporinase) by the susceptibility testing with 3 extended spectrum cephalosporins and their combination with (3-APB)
• Detection of OXA-48-like type D carbapenemases based on the determination of temocillin high-level resistance
• Detection of low-level carbapenem resistance by introduction of meropenem screening concentrations
• Analysis and interpretation after visual or automated reading according to EUCAST or CLSI standard